01 Oct The Asymmetry Of Biological Risk Management
How PrEP prevents HIV, how long it takes to work, daily versus 2-1-1 dosing, and why combining PrEP with condoms and regular testing matters....
How PrEP prevents HIV, how long it takes to work, daily versus 2-1-1 dosing, and why combining PrEP with condoms and regular testing matters....
Sexual Health Notice: This post is provided for educational and informational purposes only and is not a substitute for professional medical advice. Sexual health needs are individual — testing schedules, window periods, treatment options, and partner notification guidance vary depending on your specific situation, health history, and the infections involved. Consult a qualified healthcare provider, sexual health clinic, or public health service for personalized recommendations regarding STI testing, diagnosis, treatment, or any other sexual health concern.
For tens of thousands of years, Homo sapiens have shared pathogens through intimate contact. It is a fundamental, ancient biological reality of our species. When bodies touch, microscopic ecosystems inevitably collide and exchange microorganisms. Yet, as our societies grew more complex, we invented a powerful, invisible fiction to surround this basic biological reality: social shame.
We often fear the judgement of the tribe far more than we fear a microscopic virus. This fear of reputational damage drives entirely rational people into hiding when their bodies sound a medical alarm.
If you are searching for anonymous std testing in Singapore clinics, you are trying to navigate this ancient conflict. You want to protect your health without damaging your social standing.
[caption id="attachment_76399" align="aligncenter" width="500"]
Photo by Sanket Mishra[/caption]
Photo by Vitaly Gariev:[/caption]
Cases of congenital syphilis are ten times higher now than they were a decade ago, making it incredibly important that clinicians know to screen for syphilis so that it can be treated before pregnant women develop complications and before it spreads to their babies....
Dr. Vodstrcil[/caption]
Lenka Vodstrcil PhD
Senior Research Fellow
Deputy Head, Genital Microbiota and Mycoplasma Group
President, Sexual Health Society of Victoria
Associate Editor, Sexually Transmitted Infections
School of Translational Medicine, FMNHS, Monash University
Melbourne Sexual Health Centre, The Alfred Hospital
Melbourne School of Population & Global Health, University of Melbourne
[caption id="attachment_66983" align="alignleft" width="150"]
Dr. Bradshaw[/caption]
Catriona Bradshaw MMBS(Hons), PhD, FAChSHM, FAHMS
Professor (Research), Head of Research Translation and Mentorship
and of The Genital Microbiota and Mycoplasma Group Melbourne
School of Translational Medicine, Monash University and Alfred Hospital
Principal Research Fellow at the Burnet Institute
MedicalResearch.com: What is the background for this study?
Response: One in three women globally have bacterial vaginosis (BV), a condition that causes a malodourous discharge, and associated with serious gynaecologic and obstetric sequelae (including miscarriage and preterm birth) and increases the risk sexually transmitted infections (STIs) and HIV. Women with symptoms are treated with broad-spectrum antibiotics, however, over 50% of women experience BV recurrence within 3-6 months. The recurrence rate is even higher at 60-80% among women with an ongoing regular partner. Current practice is to simply retreat women experiencing BV recurrence with the same antibiotics, which leaves them (and clinicians) frustrated and distressed.
We and others have accumulated a body of evidence to show that BV has the profile of an STI. BV-associated bacteria are detected in men in the distal urethra and on penile-skin, and couples share these organisms. However, to date, has not been recommended for BV as it is for other STIs. This is largely because men do not usually have any symptoms, and past partner-treatment trials in the 1980s and 1990s, which only used oral antibiotics for men, failed to prevent BV recurrence, which was taken as conclusive evidence against sexual transmission. Reviews of these trials have since identified their limitations.
Given the evidence of male carriage of BV-associated bacteria at two genital sites, we hypothesised that both sites needed to be targeted with antimicrobial therapy to prevent re-infection post-treatment. The aim of our study was to assess if male partner-treatment concurrently with female treatment using a combination of oral and topical antibiotics for the first time, would decrease BV recurrence over 12 weeks compared to the current standard practice of treating women only.
Sagar Patel[/caption]
Sagar S. Patel, MBS
Department of Medical Education
Geisinger Commonwealth School of Medicine
Scranton, PA 18509
MedicalResearch.com: What was the background for this research?
Response: Syphilis is a sexually transmitted infection that is caused by a gram-negative bacterium called Treponema pallidum. This infection promotes the cell death of microglia and can cause a variety of symptoms. It is commonly observed in developing countries such as sub-Saharan Africa. Neurosyphilis is a complication of syphilis that affects the central nervous system (CNS).
The CNS undergoes multiple stages of deterioration and can include personality changes and hearing abnormalities. Diagnosing neurosyphilis is challenging because its symptoms mimic other neurodegenerative diseases. Diagnosis relies on clinical studies, cerebrospinal fluid (CSF) analysis, and neuroimaging techniques.
The escort should be informed about the latest sexual health and facts on how HIV is and is not transmitted. Proper education helps dispel any myths and misconceptions about the virus while promoting safer practices....
Dr. Stevermer [/caption]
James Stevermer, M.D., M.S.P.H.Vice chair for clinical affairs
Professor of family and community medicine
University of Missouri
Medical director of MU Health Care Family Medicine–Callaway Physicians,
Dr. Stevermer joined the U.S. Preventive Service Task Force in January 2021.
MedicalResearch.com: What is the background for this study?
Response: HIV continues to be a significant public health issue. The good news is that PrEP is a safe, highly effective way to help prevent HIV in people at increased risk. There are now two ways people can take PrEP – as a pill or as a shot. We encourage healthcare professionals to have a conversation with their patients about their individual risk for HIV and determine if they should consider taking whichever form of PrEP would work best for them.
Dr. Gandhi[/caption]
Manoj Gandhi, MD PhD
Senior Medical Director of Genetic Testing Services, Thermo Fisher Scientific.
Dr. Gandhi has been working to advance the quality of medical care globally. Using his knowledge of Clinical Medicine and Molecular Biology/Pathology, he is focused on bridging these two fields and bringing innovative solutions that help advance science, the practice of medicine with the ultimate goal of impacting patient lives, whether it be in Infectious Diseases or Oncology or Personalized Medicine. This approach allows him to explore creative ways to utilize technology to help better identify diseases and improve the direction and value of treatment.
MedicalResearch.com: What are the most common STIs prevalent in the US and worldwide today?
Response: By far, the most common STIs in the US and worldwide is Human Papillomavirus (HPV) that can cause cervical cancer in women and Herpes Simplex Virus (HSV) that is the cause of genital herpes. Outside of these two major causes of STI, the others that are very common are Chlamydia, Gonorrhea, Trichomoniasis and Syphilis. It is important to note that the reported cases represent only a subset of the individuals with an infection as many may be asymptomatic and could be spreading these STIs to others. HIV is another STI that is common but usually rests in its own category due to its impact.
Dr. Stevermer[/caption]
James Stevermer, M.D., M.S.P.H.
Vice chair for clinical affairs
Professor of family and community medicine
University of Missouri
Medical director of MU Health Care Family Medicine–Callaway Physicians,
Dr. Stevermer joined the U.S. Preventive Service Task Force in January 2021.
MedicalResearch.com: What is the background for this study?
Response: Genital herpes is a common sexually transmitted infection (STI) that unfortunately has no cure and cannot accurately be detected in people who do not have signs of the condition. The current screening tests have limitations and there is a high chance that test results will say a person has the condition when they do not. In addition, the available treatments are focused on managing symptoms and preventing the condition from reoccurring. As a result, the Task Force concluded that the harms of screening outweigh the benefits.
Sean M Hughes MA
Department of Obstetrics and Gynecology
University of Washington
Seattle, WA
MedicalResearch.com: What is the background for this study?
Response: Young women are at elevated risk of getting sexually transmitted infections at the age when they typically start to have sexual intercourse. It’s not known whether this elevated risk is a consequence of behavioral factors (such as choices around use of barrier protection), physiological factors (such as a difference in the immune system) or a combination of both. In this study, we investigated a physiological factor: the immune system in the vagina.
Dr. Ogedegbe[/caption]
Gbenga Ogedegbe, MD, MPH
Dr. Adolph & Margaret Berger Professor of Population Health
Director, Division of Health & Behavior
Director Center for Healthful Behavior Change
Department of Population Health
NYU Langone Health
NYU School of Medicine
Member of the U.S. Preventive Services Task Force
MedicalResearch.com: What is the background for this study?
Response: Syphilis has become more common over the past 20 years, after reaching a record low in 2000. The Task Force found that screening people who are at increased risk for syphilis can identify the infection early so it can be treated before problems develop. For that reason, the Task Force recommends screening people who are at increased risk for syphilis infection.
Dr. Stafford[/caption]
Irene A. Stafford, M.S., M.D.
Associate Professor
Associate Program Director Maternal - Fetal Medicine Fellowship
Department of Obstetrics and Gynecology
Division of Maternal Fetal Medicine
McGovern Medical School at UTHealth Houston
MedicalResearch.com: What is the background for this study?
Response: We have observed disproportionately high-rates syphilis in the US over the last several years, and here in Texas. As this is now leading to health alerts in our cities, it is key we bring attention to this infection regarding risks to the pregnant patient and her fetus.
Syphilis carries a nearly 40% neonatal mortality rate, so testing and treating is key in preventing this devastating neonatal infection. We need to encourage and offer testing at intake to pregnancy care, and any time a patient desires to be tested for STI.
Dr. Kubik[/caption]
Martha Kubik, Ph.D., R.N.
Professor, School of Nursing
College of Health and Human Services
George Mason University
Member, U.S. Preventive Services Task Force
MedicalResearch.com: What is the background for this study? Are these infections increasing in incidence in the US?
Response: Chlamydia and gonorrhea are two of the most common sexually transmitted infections in the U.S. More people are being diagnosed with both of these STIs than ever, with nearly 2 million cases of chlamydia and more than 600,000 cases of gonorrhea reported in 2019, according to the CDC. Because most do not have symptoms, screening is vitally important to help ensure that these infections are discovered and treated, and serious health complications prevented.
Dr. Van der Pol[/caption]
Barbara Van Der Pol, PhD, MPH
President, American STD Association
President-Elect, International Society fo STD Research
Professor of Medicine & Public Health
Director, STD Diagnostics Lab
Director, UAB STD Clinical Research Organization
University of Alabama at Birmingham
Birmingham, AL 35294
MedicalResearch.com: What is the background for this study?
Response: For many decades, public health programs focused on control and prevention of sexually transmitted infections (STI) have relied on lab based tests that required a 1-day to 1-week wait for test results. Efforts to shorten the duration of infection lead to treating at the time of the clinic visit based on the association between certain clinical signs or symptoms and the likelihood of infection.
Unfortunately, more than ½ of infected persons do not have signs or symptoms so they receive no treatment until test results are available. Thus, a test that could be performed at the clinical site with a limited wait time would improve the accuracy of treatment and shorten the duration of infection. Such a strategy will hopefully reduce the number of return clinic visits, the possibility of transmission, and the potential for consequences of untreated infection such as infertility.
Dr. Kaufman[/caption]
Gregory Kaufman, M.D.
Senior Vice President
Global Clinical and Medical Affairs
Specialty at Lupin
MedicalResearch.com: What is the background for this study? Would you briefly explain what is meant by trichomoniasis? How common is this infection?
Response: The Phase 3 trial evaluated the effectiveness and safety of a single oral dose of Solosec® (secnidazole) 2g oral granules for the treatment of trichomoniasis in adult women. Top-line results were positive and showed that Solosec was generally well-tolerated.
Trichomoniasis is the most common non-viral sexually transmitted infection (STI) in the U.S., and is caused by a protozoan parasite called Trichomonas vaginalis.[i] Trichomoniasis affects 3 to 5 million people in the U.S.,[ii] and is four- to five-times more prevalent in in women, compared to men.[iii].
Dr. Jason Ong[/caption]
Jason Ong, PhD, MMed, MBBS, FAChSHM, FRACGP
Twitter: @DrJasonJOng
Sexual Health Physician, Melbourne Sexual Health Centre, Alfred Health
Associate Professor (Hon), London School of Hygiene and Tropical Medicine, UK
Central Clinical School, Monash University, Australia
Melbourne School of Population and Global Health, University of Melbourne, Australia
Associate Editor, Sexually Transmitted Infections
Special Issues Editor, Sexual Health
Board Director, ASHM
MedicalResearch.com: What is the background for this study?
Response: HIV pre-exposure prophylaxis (PrEP) is being rolled out globally. This will protect many people from HIV, however PrEP does not protect against other sexually transmitted infections (STI). So we wanted to quantify how much STIs are in PrEP users as a means to advocate to strengthen sexual health services in these settings where PrEP is being offered.
Dr. Nobles[/caption]
Alicia Nobles, PhD, MS
Research Fellow
Department of Medicine
UC San Diego
MedicalResearch.com: What is the background for this study?
Response: Sexually transmitted diseases (STDs) are at record-high rates according to the Centers for Disease Control. Between STDs being highly stigmatized infections and people lacking access to health care, people may elect to turn to social media to connect with others. This is precisely why social media sites are so popular - because they do allow for people to talk with others rapidly.
Reddit, a social media site that rivals Twitter with 330 million active users and is the 6th most visited website in the United States, is organized into online communities, many of which discuss health topics. We monitored all r/STD (www.reddit.com/r/STD/) posts, where users can find “anything and everything STD related,” from its inception in November 2010 through February 2019.
Dr. Hoenigl[/caption]
Martin Hoenigl, MD
Assistant Professor
UCSD
MedicalResearch.com: What is the background for this study?
Response: Technology has changed the way men-who-have-sex-with-men (MSM) seek sex. Over 60% of MSM in the US use the internet and/or smartphone-based geospatial networking apps to find sex partners. Grindr™, a sophisticated geosocial networking app, is the most frequently used dating app among MSM in the United States. Previous research has shown that MSM who use Grindr™ have a greater frequency risky sexual behavior, and more sexual partners, but little is known about the association between Grindr™ use and prevention behavior such as the use of HIV pre-exposure prophylaxis (PrEP).
We evaluated risk behavior, PrEP use, and Grindr™ usage among MSM receiving community-based HIV and bacterial sexually transmitted infection (STI) screening in central San Diego. Participants who tested negative for HIV and who were not on PrEP were offered immediate PrEP.
Dr. Wigfall[/caption]
Lisa T. Wigfall, PhD, MCHES(R)
Assistant Professor, Health and Kinesiology
Texas A&M
MedicalResearch.com: What is the background for this study?
Response: Human papilloma virus (or HPV) is a very common sexually transmitted infection that can cause some types of cancer. These include anal, cervical, oral, penile, vaginal, and vulvar cancers. Some people such as people who are HIV-positive and men who have sex with men have a greater risk for developing HPV-associated cancers. The risk of developing anal cancer is significantly higher for men who have sex with men who are also HIV-positive.
Our study included adults who were at risk for becoming HIV-positive, which included having unprotected anal sex.
Dr. Silverstein[/caption]
Michael Silverstein, M.D., M.P.H.
Professor of Pediatrics
Director of the Division of General Academic Pediatrics
Vice chair of research for the Department of Pediatrics
Boston University School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Gonococcal ophthalmia neonatorum, or GON, is a severe infection of the eye that can occur in babies born to women who have gonorrhea. If left untreated, GON can cause serious problems, including blindness, that can appear as soon as 24 hours after delivery.
Fortunately, there are effective treatments available that can prevent GON in newborns. The U.S. Preventive Services Task Force reviewed the most current research on the benefits and harms of ocular prophylaxis—which is applying antibiotic ointment to the babies’ eyes at birth—to prevent GON.
We found that, if applied within 24 hours after birth, the ointment is very effective at preventing gonococcal ophthalmia neonatorum and the problems it causes. Therefore, we are recommending that clinicians provide this preventive service for all newborns.
Intracellular Gram-negative, Neisseria gonorrhoeae diplococcal bacteria, - CDC image[/caption]
Edward W. Hook, III, MD
University of Alabama at Birmingham
Medicine / Infectious Diseases
Birmingham, AL
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Zoliflodacin represents a new class of antibiotics (spiropyrimidinetriones) with in vitro activity against Neisseria gonorrhoeae, as well as other STD pathogens (Chlamydia trachomatis and Mycoplasma genitalium). Because of this promising data and the fact that the manufacturer (Entasis Pharmaceuticals) was willing to pursue the possibility of using this drug to treat gonorrhea, a Phase II trial was conducted which showed he drug to be 96% effective for genital or rectal infections. The drug was well tolerated as well making it a promising drug for gonorrhea treatment which might help to combat the increasing problem of antibiotic resistant gonorrhea.
Dr. Simon[/caption]
Melissa A. Simon, M.D., M.P.H.
Member, U.S. Preventive Services Task Force
George H. Gardner professor of clinical gynecology, Vice chair of clinical research
Department of Obstetrics and Gynecology
Professor of preventive medicine and medical social sciences
Northwestern University Feinberg School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The number of babies born with syphilis is increasing, mirroring the recent increase of syphilis among women. Syphilis infection passed from a pregnant woman to her baby, also known as congenital syphilis, can lead to serious health complications for the baby including premature birth, low birthweight, birth defects, and even death. The Task Force recommends that all pregnant women be screened for syphilis as early in pregnancy as possible to prevent congenital syphilis.
Dr. Goyal[/caption]
Monika K. Goyal, M.D., M.S.C.E., senior study author
Assistant professor of Pediatrics and Emergency Medicine
Children’s National Health System
Washington, DC
MedicalResearch.com: What is the background for this study?
Response: Patients with pelvic inflammatory disease (PID) are at an increased risk for syphilis and HIV. We know that adolescents account for 20 percent of the 1 million cases of PID that are diagnosed each year. We also know that an estimated one in four sexually active adolescent females has a sexually transmitted infection (STI). While screening for syphilis and HIV is recommended when diagnosing PID, actual screening rates among adolescents have been understudied.
This multi-center study aimed to quantify rates of HIV and syphilis screening in young women diagnosed with . pelvic inflammatory disease in pediatric emergency departments and to explore patient- and hospital-specific characteristics associated with screening for these two sexually transmitted infections.
Prof. Molina[/caption]
Professor Jean-Michel Molina MD
Head of Department of Infectious Diseases, Hôpital Saint-Louis
Paris France
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: There is a high rate of sexually transmitted infections (STIs) among Pre-exposure prophylaxis users and we wished to assess whether post-exposure prophylaxis (PEP) with doxycycline could reduce the incidence of sexually transmitted infections in this population.
We have found indeed a high rate of STIs most of them (71%) being asymptomatic and warranting therefore systematic testing. Also PEP reduced the incidence of syphilis and chlamydiae infection by 70%, not for gonorrhea due to the high rate of detection in throat swabs without any impact of PEP.
Helen Petousis-Harris. BSc, PhD
Senior Lecturer, Dept General Practice and Primary Health Care
Academic Head, Immunisation Research and Vaccinology
Immunisation Advisory Centre
School of Population Health, Faculty of Medical and Health Sciences
University of Auckland
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Early thinking came from two quarters. One, the observation that the NZ OMV vaccine appeared broadly protective – beyond the clone it was based on and two, the observation of graphs depicting annual number of cases from both Cuba and NZ. There is nothing to suggest other types of meningococcal vaccine have had any effect on gonorrhoea so we are interested in the OMV vaccines. This led to the hypothesis that as these two Neisseria species are related the meningococcal OMV in the form of a vaccine may offer some kind of cross protection.
To explore this possibility we conducted a case-control study that compared the vaccination status of cases (gonorrhoea) and controls (Clamydia). We found that the cases with gonorrhoea were less likely to be vaccinated than the controls and after we controlled for confounders – ethnicity, SE deprivation, age we found a vaccine effectiveness of 31%.
Dr. Kristen Kreisel[/caption]
MedicalResearch.com Interview with:
Dr. Kristen Kreisel PhD
Epidemiologist at Centers for Disease Control and Prevention
Centers for Disease Control and Prevention
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Pelvic inflammatory disease (PID), an infection of the female reproductive tract often associated with STDs, is putting millions of women at risk for infertility, ectopic pregnancy and chronic pelvic pain. Our study looked at data from the National Health and Nutrition Examination Survey to estimate the national burden of PID. Findings show an estimated 4.4 percent of sexually-experienced women aged 18-44, or approximately 2.5 million woman nationwide reported a history of PID.